Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus

被引：7
|
作者：
Nepal, Desh [1 ,2 ]
Gazeley, David [1 ]
机构：
[1] Med Coll Wisconsin, Dept Med, Div Rheumatol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Rheumatol, Hub Collaborat Med, 8701 Watertown Plan Rd,6th Floor, Milwaukee, WI 53226 USA
来源：
RHEUMATOLOGY | 2023年 / 62卷 / 12期
关键词：
IL-6; inhibition; SLE; tocilizumab; sirukumab; OF-RHEUMATOLOGY GUIDELINE; PHASE PROTEIN RESPONSE; MONOCLONAL-ANTIBODY; DISEASE-ACTIVITY; MURINE LUPUS; T-CELLS; INTERLEUKIN-6; TOCILIZUMAB; EFFICACY; RECEPTOR;
D O I：
10.1093/rheumatology/kead416
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Interleukin-6 is one of the cytokines implicated in murine and human SLE. Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are no studies registered in clinicaltrials.gov to assess the IL-6 targeted therapy in SLE, yet its role in the future remains to be defined. This narrative review analyses these and potential areas of future studies with IL-6 targeted therapy in SLE. A video abstract is available for this article and can be viewed at https://doi.org/10.1093/rheumatology/kead416.
引用
收藏
页码：3804 / 3810
页数：7
相关论文
共 50 条
  • [41] IL-6 Directed Therapy in Transplantation
    Miller, Cynthia L.
    Madsen, Joren C.
    CURRENT TRANSPLANTATION REPORTS, 2021, 8 (03) : 191 - 204
  • [42] Targeting IL-6 in cholangiocarcinoma therapy
    Mott, Justin L.
    Gores, Gregory J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (10): : 2171 - 2172
  • [43] Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus
    Ball, E. M. A.
    Gibson, D. S.
    Bell, A. L.
    Rooney, M. R.
    LUPUS, 2014, 23 (01) : 46 - 56
  • [44] IL-6 Quotient (The Ratio of Cerebrospinal Fluid IL-6 to Serum IL-6) as a Biomarker of an Unruptured Intracranial Aneurysm
    Kaminska, Joanna
    Dymicka-Piekarska, Violetta
    Chrzanowski, Robert
    Sawicki, Karol
    Milewska, Anna J.
    Zinczuk, Justyna
    Tylicka, Marzena
    Jadeszko, Marek
    Mariak, Zenon
    Kratz, Ewa M.
    Matowicka-Karna, Joanna
    Kornhuber, Johannes
    Lewczuk, Piotr
    Koper-Lenkiewicz, Olga M.
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 6103 - 6114
  • [45] Aberrant rag expression in systemic lupus erythematosus B-cells is due to overexpression of IL-6
    Hillion, S.
    Garaud, S.
    Jousse-Joulin, S.
    Saraux, A.
    Youinou, P.
    Jamin, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 : A4 - A4
  • [46] PLASMA-CONCENTRATION OF IL-6 IN SYSTEMIC LUPUS-ERYTHEMATOSUS - AN INDICATOR OF DISEASE-ACTIVITY
    SPRONK, PE
    TERBORG, EJ
    LIMBURG, PC
    KALLENBERG, CGM
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1992, 90 (01): : 106 - 110
  • [47] STUDY OF AN IL-6 GENE XBAI RESTRICTION FRAGMENT ASSOCIATED WITH SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE)
    LINKERISRAELI, M
    PREHN, J
    WALLACE, DJ
    LI, L
    KLINENBERG, JR
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S111 - S111
  • [48] Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value
    Jin, Saiyan
    Yu, Changcheng
    Yu, Beiwei
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 2867 - 2874
  • [49] The effect of prednisone acetate combined with cyclophosphamide on systemic lupus erythematosus and serum IL-4, IL-6, and IL-10 expressions
    Lu, Jidi
    Cheng, Peng
    Zhang, Yanxin
    Jia, Xiuqing
    Zhang, Ni
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (12): : 13781 - 13788
  • [50] IL-6 Directed Therapy in Transplantation
    Cynthia L. Miller
    Joren C. Madsen
    Current Transplantation Reports, 2021, 8 : 191 - 204
12345